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A subset of genes in the human genome are uniquely human and
not found in other species. One example is CHRFAM7A, a dominant-
negative inhibitor of the antiinflammatory α7 nicotinic acetylcholine
receptor (α7nAChR/CHRNA7) that is also a neurotransmitter receptor
linked to cognitive function, mental health, and neurodegenerative
disease. Here we show that CHRFAM7A blocks ligand binding to both
mouse and human α7nAChR, and hypothesized that CHRFAM7A-
transgenic mice would allow us to study its biological significance in
a tractable animal model of human inflammatory disease, namely
SIRS, the systemic inflammatory response syndrome that accompanies
severe injury and sepsis. We found that CHRFAM7A increased the
hematopoietic stem cell (HSC) reservoir in bone marrow and biased
HSC differentiation to themonocyte lineage in vitro.We also observed
that while the HSC reservoir was depleted in SIRS, HSCs were spared
in CHRFAM7A-transgenic mice and that these mice also had increased
immune cell mobilization, myeloid cell differentiation, and a shift to
inflammatory monocytes from granulocytes in their inflamed lungs.
Together, the findings point to a pathophysiological inflammatory
consequence to the emergence of CHRFAM7A in the human genome.
To this end, it is interesting to speculate that human genes like
CHRFAM7A can account for discrepancies between the effectiveness
of drugs like α7nAChR agonists in animal models and human clinical
trials for inflammatory and neurodegenerative disease. The findings
also support the hypothesis that uniquely human genes may be con-
tributing to underrecognized human-specific differences in resiliency/
susceptibility to complications of injury, infection, and inflammation,
not to mention the onset of neurodegenerative disease.
inflammation | injury | hematopoietic stem cells | acetylcholine receptor |
α7 nicotinic acetylcholine receptor
Although it is generally agreed that the emergence of new,species-specific genes helped drive the phenotypic evolution
of humans, just as they have done in other species (1, 2), there is
a lack of direct evidence that links these genes to normal human
biology and/or to the onset of traits that might be uniquely human
in disease. While these genes may well have enabled adaptations of
the species, contributed to processes that are now considered
normal human physiology, and even altered human resilience and
susceptibility to disease and infection (3), their direct study is un-
usually difficult. First and foremost, these genes are either absent in
animal models of human disease (4–6), or alternatively present in
animals but not humans (7, 8). To date, the study of their signifi-
cance can only be inferred by human clinical research.
The CHRFAM7A gene is a case in point (9, 10). It originally arose
in the hominin genome when five exons of the UL Kinase-4 gene on
chromosome 3 translocated to, and then fused with, the Dupa gene
(11, 12), a gene that is found in many species that originated with 5
exons partially duplicated from the 10-exon α7 nicotinic acetylcholine
receptor (α7nAChR/CHRNA7) gene on the forward strand of
chromosome 15 (Fig. 1A). Accordingly, CHRFAM7A is a hybrid
gene that is in close physical proximity to CHRNA7 and encodes
a protein with structural similarity to α7nAChR. Both genes are
independently regulated by unique promoters that drive their differ-
ential expression (13, 14).Moreover, several genetic studies have tied the
CHRFAM7A/CHRNA7 locus and a 2-bp mutation in CHRFAM7A
on chromosome 15 to nicotine dependence, schizophrenia, cogni-
tive dysfunction, and bipolar and neurodegenerative disease (9, 10).
Several recent studies have suggested that CHRFAM7A encodes a
dominant-negative inhibitor of ligand binding to α7nAChR in vitro
(15–18), which can also be observed at the neuromuscular junction of
transgenic mice (19). As such, CHRFAM7A has been implicated in
the regulation of numerous α7nAChR-dependent antiinflammatory
processes as well as in mental health, cognition, and neurodegener-
ative disease (20). In peripheral tissues, there has been significant
interest in the role of α7nAChR in the neural control of in-
flammation (21), where it has been implicated in gauging both
local and systemic inflammatory responses after burn, hemor-
rhage, sepsis, arthritis, and wound healing, to name a few (22,
23). With no cognate CHRFAM7A hybrid gene in other species,
however, the physiological and pathophysiological consequences
of its expression in humans are not known and not manifested in
standard models of human disease (3, 10, 13). Accordingly, because
α7nAChR agonists have been very effective in mouse models of
human disease but nevertheless disappointing in human clinical
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studies (24), we deemed it necessary to assess the significance of
CHRFAM7A to cholinergic signaling in an animal model of inflam-
mation. To this end, we engineered transgenic mice to express
CHRFAM7A in both central nervous system and peripheral tissues, as
it is normally observed in humans.We then explored the consequences
of its expression for the inflammatory response to injury, namely the
phenomena of bone marrow exhaustion and emergency myelopoiesis
that characterize the systemic inflammatory response syndrome (SIRS)
that leads to organ failure and death in humans after severe injury.
Results
CHRFAM7A Is Widely Distributed in Human Tissues. Like many new
genes that emerge during speciation (25–29), we found that the
expression of CHRFAM7A is high in reproductive tissues (Fig.
1B). In addition, we noted overrepresentation of CHRFAM7A
relative to CHRNA7 in human bone marrow (Fig. 1C). This ob-
servation supports our earlier hypothesis that the emergence of
CHRFAM7A could have contributed changes to immunity and
human resilience/sensitivity to injury, infection, and/or inflammatory
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Fig. 1. CHRFAM7A is widely distributed in human tissues and overrepresented in bone marrow. (A) Schematic representation of the origin of CHRFAM7A in the
human genome. The 10-exon α7nAChR (CHRNA7) gene of many species underwent a partial duplication and translocation to create a 5-exon gene in near proximity
to CHRNA7. A second partial translocation of 5 exons originating from a ULK-4 (FAM) gene of chromosome 3 then fused with this sequence to create a unique
chimeric 10-exon gene called CHRFAM7A that is found in both Homo sapiens (https://www.ensembl.org/Homo_sapiens/Info/Index) and Homo neanderthalis gene
databases (neandertal.ensemblgenomes.org), and encodes identical 412-amino acid proteins with a new and unique 27-amino acid sequence in its extracellular ligand-
binding domain. (B and C) Mining the distribution of CHRFAM7A and CHRNA7 expression in human tissues. Gene expression data were scraped from the Human
Protein Atlas (Methods) as curated on GenTree in July 2018. It shows that CHRFAM7A is widely expressed in humans, particularly in reproductive and immune tissues.
These data, along with expression in discrete areas of the brain, were confirmed by qPCR (SI Appendix, Fig. S1). (D–G) Proportional representation of CHRFAM7A
and CHRNA7 expression in human tissues. There is bias in CHRFAM7A expression in reproductive tissues like endometrium and testes (D) but expression appears
evenly distributed between CHRFAM7A and CHRNA7 in endocrine tissues (E). This is in contrast to digestive tissues like the small intestine, colon, and duodenum,
which show a bias toward the parental CHRNA7 gene expression (F). Immune tissues like the lymph nodes, bone marrow, and appendix show a preponderance of
CHRFAM7A gene expression (G). (H) Expression of CHRFAM7A expression in circulating immune cells from healthy volunteers. CHRFAM7A expression is readily
detected in CD14+ myeloid cells, with the expression of CHRFAM7A in lymphocytes (CD3+ cells) and granulocytes (CD15+ cells) at the detection limit (10 copies per
μgmRNA) of the assay. (I) The bone marrow of transgenic mice expresses a CHRFAM7A protein. Immunoblotting of bone marrow lysates with an antibody raised to
a unique 27-amino acid sequence of CHRFAM7A not present in CHRNA7 reveals translation of a protein with the predicted 43-kDa molecular size of CHRFAM7A. It
is not detected in bone marrow lysates prepared from wild-type C57 mice. FPKM, fragments per kilobase of transcript per million mapped reads.
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responsiveness (3, 9, 30). Because the product of CHRFAM7A reg-
ulates ligand binding to α7nAChR (15–18) encoded by CHRNA7, we
compared the relative expression of CHRNA7 and CHRFAM7A in
human tissues (Fig. 1 D–H). Reproductive organs showed bias
toward increased CHRFAM7A expression (Fig. 1D), while endo-
crine tissues displayed no difference (Fig. 1E). Digestive tissues
showed increased CHRNA7 expression over CHRFAM7A (Fig.
1F), possibly reflecting the protective role of CHRNA7 in the neural
control of gut inflammation (31–33). Bone marrow, however, like in
the appendix, was particularly elevated in relative CHRFAM7A
expression (Fig. 1G). In blood, circulating CD14+ monocytes, but
not CD3+ lymphocytes or CD16+ granulocytes, express CHRFAM7A
(Fig. 1H). Additional surveys of human peripheral and central
nervous system tissues confirmed this wide tissue distribution of
CHRFAM7A (SI Appendix, Fig. S1).
CHRFAM7A Expression Increases Differentiation of Hematopoietic Stem
Cells to Monocytes over Granulocytes in Vitro. To develop a tractable
experimental model capable of evaluating the functional conse-
quences of CHRFAM7A, we first showed that the CHRFAM7A
gene encodes a functional protein in mouse cells (SI Appendix, Fig.
S2) that inhibits ligand binding to both human α7nAChR transfected
in BALB/c 3T3 fibroblasts (SI Appendix, Fig. S2 A–E) and en-
dogenous mouse α7nAChR on RAW264-7 macrophages (SI Ap-
pendix, Fig. S2 F–L). Most notably, we observed the same increase
in cell–cell adhesion in mouse RAW264-7 macrophages (SI Ap-
pendix, Fig. S2H) as we previously reported in CHRFAM7A-
transfected human THP1 monocytes (13). Because these findings
establish that CHRFAM7A is active in a mouse genetic back-
ground, we then generated two independent lines of transgenic
CHRFAM7A mice (SI Appendix, Figs. S3 and S4) that produce a
43-kDa CHRFAM7A protein in tissues under control of the EF1α
promoter, in tissues such as bone marrow (Fig. 1I). These naive
mice were indistinguishable from their wild-type siblings and
showed no morphological or gross hematological phenotype (SI
Appendix, Fig. S5).
Based on the elevated expression of CHRFAM7A in human bone
marrow (Fig. 1 B andG) and monocytes (Fig. 1H), we focused on the
effects of CHRFAM7A expression on myelopoiesis, and specifically
on whether CHRFAM7A would affect colony formation of bone
marrow cells differentiated with GM-CSF in vitro (Fig. 2). To this
end, bone marrow from both transgenic and sibling mice was placed
into MethoCult for 7 d and colony-forming potential was measured.
Viability (SI Appendix, Fig. S6) and morphology (Fig. 2A) of the
colonies that emerged were indistinguishable. Unexpectedly, sig-
nificantly more colonies from CHRFAM7A-transgenic mouse bone
marrow expanded from equal numbers of starting cells in differ-
entiation media (Fig. 2B). Analyses of these colonies using flow
cytometry revealed a significant increase in the percentage of some,
but not all, lineage-committed CD45+ and CD11b+ cells (Fig. 2 C–
G). While there was increased differentiation of cells to CD11b+
Ly6C+ monocytes (Fig. 2E) and CD11b+F4/80+ macrophages (Fig.
2F), compared with cells from wild-type controls, there was no
difference in the percentage of CD11b+Ly6G+granulocytes (Fig.
2G). These data suggest that CHRFAM7A promoted expansion of
monocytes over granulocytes.
CHRFAM7A Expression Increases the Hematopoietic Stem Cell
Reservoir. To assess whether CHRFAM7A also affects myeloid
cell expansion in vivo, we analyzed the bone marrow of CHRFAM7A-
transgenic mice for hematopoietic stem cells (HSCs) and com-
pared the findings with sibling controls and wild-type C57BL/6J
mice (Fig. 3 and SI Appendix, Fig. S7). To detect HSCs, we used
c-Kit and Sca1 antibodies on the subpopulation of lineage-
negative (Lin−) cells and quantified the Lin−Sca1+c-Kit+ (LSK)
and Lin−c-Kit+ (LK) cells in bone marrow of wild-type and
CHRFAM7Amice (Fig. 3 A–F). As shown in Fig. 3G andH, there
were significantly more LSK and LK cells in the bone marrow of
CHRFAM7Amice compared with wild-type controls. This increase
was also observed in two independent lines of CHRFAM7A-
transgenic mice. Because the percentages of cells recovered from
sibling or commercial C57BL/6J mice were indistinguishable (SI
Appendix, Fig. S7 A and B), we concluded that the increased colony
formation in vitro (Fig. 2) was attributable to an increase in the HSC
reservoir in the bone marrow of CHRFAM7A-transgenic mice.
CHRFAM7A Protects Burn-Induced HSC Exhaustion and Redirects
Myelopoiesis to Monocyte Lineage. In humans (SI Appendix, Fig.
S8), the percentage of CD34+ circulating progenitor cells de-
creases after severe burn injury, presumably as cells are mobi-
lized into affected tissues. To explore whether the transgenic
expression of CHRFAM7A would affect the fate of LSK cells in
vivo, we used an experimental model of burn injury that induces
emergency myelopoiesis and the depletion of HSCs in bone
marrow like SIRS to cause significant morbidity and mortality in
humans (34, 35). In this model, a cutaneous burn mobilizes
myeloid cells from the bone marrow and stimulates immune cell
trafficking to peripheral tissues like lung (36–39) to cause long-
term depletion of HSCs and bone marrow exhaustion (37). Ac-
cordingly, it is possible to monitor changes in bone marrow by
flow cytometry (Fig. 4 A and B) and quantify the decrease of LK
and LSK cells as they differentiate and mobilize after burn injury
to wild-type and CHRFAM7A-transgenic mice (Fig. 4 C and D).
Unlike wild-type mice, there was no near depletion of LK or
LSK cells in the bone marrow of CHRFAM7A mice after burn
injury. Instead, the percentage of LSK cells most notably decreased
to levels that resembled those of uninjured wild-type mice. These
findings suggest that CHRFAM7A spares the bone marrow HSC
reservoir from depletion following severe injury.
We next determined whether the sparing of the HSC reservoir
in CHRFAM7A mice was accompanied by changes in commit-
ment of myeloid cells to monocyte lineage, like that observed in
vitro. In both wild-type and CHRFAM7A mice, these analyses
(Fig. 4 E–N) identified a burn-induced reduction in all cell types
evaluated, including resident CD45+ and CD45+CD11b+ leu-
kocytes (Fig. 4 E–H), CD11b+Ly6CHigh inflammatory monocytes
(Fig. 4 I and J), and Ly6G+Ly6C− granulocytes (Fig. 4 K and N),
presumably as cells are mobilized to peripheral tissues. The mono-
cyte response of both wild-type and CHRFAM7A-transgenic mice
to burn injury was qualitatively similar but quantitatively distinct.
This was because CHRFAM7Amice started with a higher number
of basal CD11b+Ly6CHigh inflammatory monocytes in their bone
marrow (Fig. 4 I, J, L, andM). In contrast, we noted that the burn-
induced decreases in CD11b+Ly6CLow monocytes (Fig. 4 I and K)
and Ly6G+Ly6C− granulocytes (Fig. 4 L and N) were not differ-
ent, reflecting a shift in the mobilization of CD11b+Ly6CHigh (Fig.
4J) and Ly6G−Ly6C+ (Fig. 4M) inflammatory monocytes over
CD11b+Ly6CLow (Fig. 4K) or Ly6G+Ly6C− (Fig. 4N) cells. These
data establish that the CHRFAM7A-dependent increase in
monocyte lineage shown in vitro is also detected in vivo. The phe-
notype appears to be bone marrow-dependent, because the splenic
myeloid cell response to burn was not affected by CHRFAM7A
expression (SI Appendix, Fig. S9). We concluded that the main
consequence of CHRFAM7A expression is likely tied to its ability
to increase myelopoiesis, and with it spare the HSC reservoir in the
bone marrow niche following injury.
CHRFAM7A Increases and Redirects Differentiation of Myeloid Cells
Mobilized to Injured Lung.Despite CHRFAM7A sparing the HSC
reservoir after injury, the CHRFAM7A-transgenic mice also
show an increase in myeloid cell mobilization to affected lungs (Fig.
5). This myeloid cell mobilization appears injury-dependent. The
percentages of CD45+ leukocytes were similar in uninjured wild-
type and CHRFAM7A mouse lungs. In contrast, the percentages
of CD45+ (Fig. 5 A and B) and CD45+CD11b+ (Fig. 5 C and D)
leukocytes mobilized to lungs post injury were significantly
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increased in CHRFAM7A mice. This is consistent with an
early and rapid mobilization of inflammatory cells that would
characterize a SIRS-like response (37, 40).
There was also a significant difference in the appearance of
more differentiated myeloid cells in the CHRFAM7A-transgenic
mice compared with their wild-type counterparts (Fig. 5 E–J).
Basal percentages of lung immune cells measured in sham mice
were the same in all groups, but there were burn-induced differ-
ences and CHRFAM7A-dependent differences in monocytic
but not granulocytic lineage. These included increased CD11b+
Ly6CHigh inflammatory and CD11b+Ly6CLow patrolling monocytes
(Fig. 5 E–G and J) in the injured lung. In contrast, while the per-
centages of granulocytes (i.e., Gr1+Ly6C−; Fig. 5 H and I) were
increased in injured lungs, there was no difference between wild-
type and CHRFAM7Amice. Like bone marrow in vitro and in vivo,
the expression of CHRFAM7A redirects myeloid differentiation to
monocytes, presumably to alter the cellular response in the inflamed
target tissue.
Discussion
We observed an increased HSC reservoir in the bone marrow of
two independent lines of CHRFAM7A-transgenic mice. These
findings imply that the emergence of CHRFAM7A expression in
humans is relevant to physiological and pathophysiological processes
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Fig. 2. MethoCult identifies an increase in colony-forming activity and bias to monocyte lineage. (A) Morphology of colonies from wild-type and CHRFAM7A-
transgenic mice. The appearance of macrophage (M) and granulocyte-monocyte (GM) colonies expanded from 3 × 103 bone marrow cells from wild-type and
CHRFAM7A-transgenic mice in GM differentiating MethoCult is morphologically indistinguishable. Cells were examined under phase-contrast microscopy and
photographed. (B) Colony numbers in GM differentiating MethoCult. After 7 d in MethoCult culture, the numbers of colonies that arose after plating 3 × 103
wild-type or CHRFAM7A-transgenic bone marrow cells per dish were determined. Differences in 16 replicates performed from 8 donor mice were analyzed by
unpaired, two-tailed t test (P < 0.01). The horizontal line shows the mean. (C–G) Flow cytometry of bone marrow cells differentiated in vitro. After the
exclusion of debris, doublets, and nonviable cells (SI Appendix, Fig. S10), flow cytometry was used to identify and measure changes in myeloid differentiation
including CD45+ (C) and CD45+CD11b+ (D) leukocytes, and CD11b+Ly6C+ monocytes (E) and F4/80+CD11b+ macrophages (F). There was no difference in
CD11b+Ly6G+ granulocytes (G). Differences in eight mice were analyzed by unpaired two-tailed t test (*P < 0.05, **P < 0.01; NS, not significantly different).
The horizontal line shows the mean.
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in which the HSC reservoir is thought to be critically important.
Examples include the HSC response to injury as shown here, but
likely extend to other inflammatory responses, to infection and
changes observed during lifespan, healthspan, and normal aging (34,
41–48). Because α7nAChR has been detected in a subset of bone
marrow stem cells and cholinergic signaling in bone marrow tied to
HSC and leukocyte migration (49, 50), the findings are also com-
patible with, and add to, predictions that the interference of agonist
binding to α7nAChR by CHRFAM7A expression will impact
α7nAChR-dependent activities. That being said, they do not
preclude the possibility that there exist CHRFAM7A activities
that are independent of α7nAChR or couple with other
nAChRs. These findings are compatible with the immunopheno-
typing of bone marrow, spleen, and lung myeloid cells showing a
CHRFAM7A-dependent bias toward monocyte differentiation
after induction of SIRS and an exacerbation of myeloid cell
mobilization to lung in the experimental mouse model of emer-
gency myelopoiesis. Accordingly, the data all support a function for
CHRFAM7A in human inflammation, in the development, main-
tenance, and mobilization of bone marrow HSCs, and, by inference,
human-specific resilience and susceptibility to disease. With this in
mind, we speculate that the wide distribution of CHRFAM7A in
humans could be regulating α7nAChR-dependent inflammatory
responses in a species-specific manner and gauging α7nAChR ac-
tivity in disease processes where it has already been implicated:
arthritis, cancer, cardiovascular disease, injury repair, sepsis, tissue
regeneration, and impaired wound healing (51–55).
There are a large number of studies that have characterized
the inflammatory consequences of severe burn, trauma, and in-
fection for both the depletion and mobilization of cells in tissues
like lung (37, 38, 45, 56). Acute injury, including severe cuta-
neous burn, results in a rapid response by the immune system.
While these immune cells respond and traffic to sites of tissue
injury, the bone marrow must also recover from the injury in a
process called emergency myelopoiesis (34, 41–48). This myelopoi-
esis occurs through differentiation of HSCs in bone marrow and
provides a renewed source of immune cells capable of responding to
subsequent insults (57, 58). Myelopoiesis, however, also occurs in
extramedullary tissues such as the spleen (59). Here, we find that
CHRFAM7A expression increased the bone marrow reservoir of
HSCs, but there was no effect on myelopoiesis in the spleen. In-
terestingly, expansion of the HSC reservoir and increased myelo-
poiesis have been shown to improve animal survival to challenges, for
example with LPS (58). It is therefore interesting to speculate that
this retention of HSCs in CHRFAM7A-transgenic mice could even
be protective. If so, the inflammatory responses that accompany se-
vere injury could have helped drive the emergence of CHRFAM7A,
its selection, and its subsequent retention in the hominid genome. To
this end, we have noted that some injuries, such as burn, track to
species-specific behaviors that are both unique to, and ubiquitous
within, human societies.
Surprisingly, we noted that in the SIRS response after severe
burn injury at 4 h, there is an increase in immune cell trafficking
to the lung in the CHRFAM7A-transgenic mice, while these
same animals retain more HSCs in their bone marrow than their
wild-type counterparts. These observations raise the possibility
that in addition to altering the acute injury response, the retention
of an HSC reservoir could increase the availability of HSCs to
better respond to subsequent disruptions, called a “second hit”
(42, 45, 60). This clinical phenomenon is critical to survival after
injury and polytrauma because it has the potential to limit the
SIRS response that leads to acute lung injury and the onset of
multiorgan dysfunction syndrome that accompanies severe injury
and leads to high mortality (34, 42, 43, 60).
Nearly 20 y ago, the possibility that taxonomically restricted
genes specify species-specific responsiveness garnered attention
with the discovery of cmah (7), a gene whose product is absent in
humans but nevertheless regulates resilience, susceptibility, and
the response to infection and injury in other species (8, 61, 62).
The present study with CHRFAM7A in transgenic mice was made
possible because we were first able to show that CHRFAM7A
recognizes and regulates the mouse form of α7nAChR (19). We
posit that it is this interaction that most likely generates the HSC
phenotype reported here and predict that CHRNA7 knockout
mice could have the same phenotype. That being said, it is
noteworthy that this transgenic mouse approach cannot address
the possibility that CHRFAM7A, perhaps as homopentamers or
heteropentamers with other cholinergic subunits, has distinct
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Fig. 3. Hematopoietic stem cells are increased in CHRFAM7A-transgenic bone marrow. (A–F) Flow cytometry of mouse lineage− Sca1+ c-Kit+ (LSK) hema-
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Fig. 4. CHRFAM7A spares bone marrow HSCs after burn with bias for monocyte lineage. (A and B) Flow cytometry analysis of mouse c-Kit+ Sca1+ lineage−
hematopoietic stem cells after thermal injury. The gating strategy that separates LSK and LK hematopoietic progenitor populations in mouse bone marrow
without (A) or after (B) a 4-h burn injury enables quantification of the LK (c-Kit+Sca1−) and LSK (c-Kit+Sca1+) percentage of cells gated out of the ∼10%
lineage-negative staining cells. (C and D) Quantification of mouse hematopoietic LSK and LK stem cells in bone marrow of wild-type and CHRFAM7-transgenic
mice. Quantification of LSK (C) and LK (D) hematopoietic progenitor populations from WT and CHRFAM7A mouse bone marrow after sham or a 4-h thermal
injury. With no difference between C57BL/6 or siblings and transgenic line 3 or 4, data were combined for analyses by one-way ANOVA (**P < 0.01, ***P <
0.001). (E–N) Quantification of mouse myeloid cells in bone marrow after burn injury. After the exclusion of debris, doublets, and nonviable cells (SI Appendix,
Fig. S10), resident myeloid cell subset lineages were assessed by flow cytometry in bone marrow without (sham) or with thermal injury (burn) in wild-type and
CHRFAM7A-transgenic mice. Differences in immune cells including CD45+ leukocytes (E and F), CD45+CD11b+ monocytes (G and H), CD11b+Ly6CHigh/Low (I–K),
and Ly6CHighLy6GLow and Ly6GHighLy6CLow (L and M) inflammatory, resident, and patrolling macrophages and granulocytes were calculated. With no ob-
servable differences between wild-type C57BL/6 siblings and commercial mice or between CHRFAM7A-transgenic lines 3 and 4, respectively (SI Appendix, Fig.
S7), data were combined and differences were analyzed by one-way ANOVA (*P < 0.05, **P < 0.01, ***P < 0.001).
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activities or regulates other uniquely human genes. To this end, we
note that gene expression analyses after stable transfection of the
monocyte THP1 cell line (13) suggested that CHRFAM7A regulates
TPTEP1 (63), a uniquely human endogenized retroviral sequence
that encodes an AT-hook protein reminiscent of transcription fac-
tors (64). These findings suggest the existence of human-specific
signaling that would be absent in the transgenic background. This
possibility makes it critically important to determine the conse-
quences of uniquely human gene expression to human physiology
and, even more importantly, the development of better methods to
study their effects in animal models of human disease.
Finally, it is noteworthy that the findings presented here point
to how the emergence of a species-specific gene might gauge myeloid
cell mobilization, and with it, inflammatory responsiveness. It is a
mechanism that might be contributing to the observation that
systemic inflammatory responses to severe injury and infection in
humans and mice are genetically distinct (65–67). Qualitatively,
different species share numerous inflammatory responses (56,
68) that can be ascribed to common cellular mechanisms. These
include immune cell mobilization to the sites of tissue injury and
infection (40) for pro- and antiinflammatory functions in pathogen
phagocytosis, infection control, and tissue repair (69). CHRFAM7A,
however, presents a unique molecular variation to an antiinflammatory
pathway that is otherwise shared by numerous species. This
variation could be critical in targeting human therapeutics. For
example, it is interesting to speculate that the translational gap that
characterizes the efficacy of drugs targeting α7nAChR in animal
models and humans (24) might be attributable to the presence of
CHRFAM7A in humans but not other species. If so, regulating
CHRFAM7A expression in humans could confer a newfound
efficacy in humans and utility of a wide class of drugs originally de-
veloped to target, and proven effective to treat, α7nAChR-mediated
inflammatory and neurodegenerative disease in animal models.
Methods
Details for all materials and methods are described in SI Appendix.
Gene Expression in Normal Human Tissues. Two strategies were used to assess
gene expression in normal tissues: (i) mining (August 2018) expression data
in the Human Protein Atlas (https://www.proteinatlas.org) as reported in
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Fig. 5. CHRFAM7A increases myeloid migration to lung after burn injury with a bias toward monocyte lineage. Flow cytometric analyses of enzymatically
digested lung cells were obtained from mice 4 h after a 7-s thermal injury to show that, after the exclusion of debris, doublets, and nonviable cells (SI
Appendix, Fig. S10), different myeloid immunophenotypes can be distinguished, identified, and quantified. As such, total CD45+ staining leukocytes (A and B),
CD45+CD11b+ monocytes (C and D), and CD11b+Ly6CHigh/Low inflammatory/patrolling monocytes (E–G) are all significantly increased in lung after burn injury
in both wild-type and CHRFAM7A-transgenic mice. Whereas basal percentages are not qualitatively different, there is a significantly increased quantitative response
in lungs of CHRFAM7A mice to the burn injury in CD45+ staining leukocytes (B, P < 0.05), CD45+CD11b+ monocytes (D, P < 0.05), and CD11b+Ly6CHigh/Low
inflammatory/patrollingmonocytes (F, P < 0.001;G, P < 0.05). In contrast, the percentage of Gr1+Ly6C− granulocytes (H and I) increased in response to burn injury (P <
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(P < 0.01) in lungs of CHRFAM7A-transgenic mice. Differences between the groups were analyzed using one-way ANOVA (*P < 0.05, **P < 0.01, ***P < 0.001).
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GenTree (gentree.ioz.ac.cn), a database comparing species-specific gene
assembly (29), and (ii) qRT-PCR of cDNAs in OriGene Tissue Scan Arrays
prepared of normal human peripheral tissues and human brain.
Recruitment of Human Volunteers for Blood Donation. Blood was collected
from normal and burn patients after informed consent. The University of
California, San Diego, Institutional Review Board approved the consent
forms, specimen collection protocols, and guidelines for study procedures.
Isolation of CD14+, CD15+, and CD3+ Cells from Blood, HSC Colony Formation,
and in Vitro Studies.An autoMACS Pro Separator (Miltenyi Biotec) was used to
isolate CD3+, CD14+, and CD15+ cells from human blood according to the
manufacturer’s recommendations, and cells were processed for RNA iso-
lation, cDNA synthesis, and PCR as described below. In vitro colony forma-
tion of bone marrow cells from sibling (nontransgenic) and transgenic mice
was assessed in MethoCult colony formation assays according to the man-
ufacturer’s (Stem Cell Technologies) recommendations. Cells were diluted in
granulocyte-macrophage (GM) MethoCult media, incubated 7 d, photographed,
and assessed by flow cytometry. Mouse BalbC 3t3 fibroblasts and RAW264.7
macrophages were cultured, transfected, and analyzed for CHRFAM7A expression
and bungarotoxin binding by immunoblotting, fluorescence microscopy, and flow
cytometry, as described in the methods of SI Appendix. The effects of CHRFAM7A
on RAW cell morphology was assessed by microscopy (SI Appendix, Fig. S2). To
purify leukocytes from human blood and process for extraction, the μMACSmRNA
Isolation Kit (Miltenyi Biotec; 130-075-201) was used per the manufacturer’s pro-
tocol withmechanical shearing and cDNA synthesis as described in further detail in
SI Appendix.
Transgenic Mice and PCR. Transgenic mice were generated by contract with
Cyagen with CHRFAM7A under control of the elongation factor 1A (EF1A)
promoter (SI Appendix, Fig. S1). Of the four mouse lines obtained (SI Ap-
pendix, Fig. S2), lines 3 and 4 were used in all of the experiments to ensure
that differences could be attributed to CHRFAM7A, and nontransgenic siblings
were used as controls as indicated. Primers for PCR included CHRFAM7A [for-
ward (F)] 5′-ATAGCTGCAAACTGCGATA-3′ and [reverse (R)] 5′-CAGCGTA-
CATCGATGTAGCAG-3′; human CHRNA7 (F) 5′-ACATGCGCTGCTCGCCGGGA-3′
and (R) 5′-GATTGTAGTTCTTGACCAGCT-3′; mouse CHRNA7 (F) 5′-CGTGGGCC-
TCTCTGTAGTGG-3 and (R) 5′-CTGGAGTTGGGGCACAGTGC-3′; and rat/mouse
GAPDH QuantiTect QT01658692 and human GAPDH (F) 5′-CATGAGAAGT-
ATGACAACAGCCT-3′ and (R) 5′-AGTCCTTCCACGATACCAAAGT-3′. Relative gene
expression was calculated by either comparing the thermal cycle number (Ct)
with that of GAPDH or with a standard curve generated with plasmid, and
expressed as either a reciprocal of dCt, plasmid copy number, or fold in-
crease using the ΔΔCt method.
Animal Model of Cutaneous Thermal Injury. All animal studies were conducted
in accordance with the NIH Guide for the Care and Use of Laboratory Animals
(70) and preapproved by the University of California, San Diego, Animal Sub-
jects (Institutional Animal Care and Use) Committee. CHRFAM7A-transgenic
lines were propagated as heterozygotes, and sibling nontransgenic and
CHRFAM7A-transgenic mice were obtained through the University of
California, San Diego, breeding core once identified as transgenic by tail clip
analyses (Transnetyx). Only male mice were used in the studies reported here,
because female mice have differential sensitivity to thermal injury. Age-
matched C57BL/6 mice were also purchased from Jackson Laboratories for
cross-over studies. Animals received buprenorphine for pain control, and 8 cm2
exposed to steam for 7 s. Animals then received an s.c. injection of 1 mL normal
saline and sacrificed 4 h later.
Flow Cytometry. Bone marrow cells from wild-type, sibling (nontransgenic),
or transgenic mice were analyzed after 7 d of differentiation in GM
MethoCult in vitro using a myeloid cell antibody panel capable of detecting
monocytes, macrophages, granulocytes, and dendritic cells with anti-Gr1,
anti-CD45, anti-Ly6G, anti-F4/80, anti-CD11c, anti-Ly6C, and anti-CD11b, and
propidium iodide (PI) to cells to assess cell viability (SI Appendix, Table S1).
Compensation settings were established using MACS Comp Bead Kits. To
assess bone marrow directly, cells were collected from tibia and femur and
stained for analyses in a multipanel flow cytometer (MACS; Miltenyi Biotec)
using an antibody panel capable of detecting c-kit+ and Sca1+ cells in a
lineage-negative (Lin−) HSC population called LSK cells (SI Appendix, Table
S2). In contrast, lung or spleen tissues were dissociated into single-cell sus-
pensions using an enzymatic digestion and a mechanical gentleMACS
dissociator according to the manufacturer’s instructions. Splenic single-cell
suspensions were then submitted to myeloid cell immunostaining using the
antibody panel of SI Appendix, Table S1 (above), while another panel (SI
Appendix, Table S3) was adapted for the detection of lung alveolar macro-
phages and dendritic cells). A myeloid subset of cells in lung was measured
using a panel composed of anti-Gr1, anti-MHCII, anti-F4/80, anti-CD11c, anti-
Ly6C, and anti-CD11b (SI Appendix, Table S4). Compensation settings were set
byMACS Comp Bead Kits. With no difference between C57BL/6 or siblings and
transgenic lines 3 or 4 (SI Appendix, Figs. S6 and S7), data from both mouse
lines were combined for analyses unless indicated otherwise.
Statistical Analysis. All data and calculations were performed using GraphPad
Prism software (version 6.0) including ANOVA and t tests where appropriate
as indicated in the figure legends.
Data Availability. The authors confirm that all relevant data are included in
the paper and/or its SI Appendix and available on request from the authors.
Source data for Fig. 1 are provided from the Human Protein Atlas (https://
www.proteinatlas.org) as scraped from GenTree (gentree.ioz.ac.cn) and
described in Methods.
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